Logo

BMS' Onureg (azacytidine) Receives EC's Approval for as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

Share this

BMS' Onureg (azacytidine) Receives EC's Approval for as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

Shots:

  • The EC approval is based on a P-III QUAZAR AML-001 study assessing Onureg (300mg- qd) vs PBO + BSC for 14days of a 28-day cycle in patients aged ≥55yrs. with AML who achieved CR or with CRi following induction therapy with/out consolidation treatment and who are not candidates for- including those who choose not to proceed to HSCT
  • The study showed 1EPs of OS is greater than 2yrs. (24.7mos. vs 14.8mos.)- mDOR (12 vs 6 cycles); m- relapse-free survival (10.2 vs 4.8 mos.)
  • Onureg is the first and only once-daily- frontline oral maintenance therapy in the EU for patients with a broad range of AML subtypes

  Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions